A CRISPR Conundrum: Intellia's Trial Halt Jolts the Biotech World
The Shaking Ground: Intellia's Gene-Editing Dream Hits a Harsh Reality Check with Trial Setback
The Great Market Paradox: Q3 2025 Sees Bears Roar on Headlines While Bulls & Gold Bugs Silently Reap Riches
Midday Market Movers: Biotech Rockets, Tech Soars, and a Coffee Giant Stumbles
Cathie Wood's ARK Invest Stacks Up on Alibaba, Baidu, and Biotech Gems in Active Week